AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18506026 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative cisplatin-based chemotherapy with other drugs
Number of subjects: 4584
Study 17068392 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg bid
Number of subjects: 100
Study 17068392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 12856812 — intervention group
Group type: EXPERIMENTAL
Intervention: Biological background knowledge
Number of subjects: 337
Study 12856812 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological theory of drug action curriculum
Number of subjects: 337
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Short sleep duration
Number of subjects: 3030
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia symptoms
Number of subjects: 3030
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective insufficient sleep
Number of subjects: 3030
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep enhancing medication use
Number of subjects: 3030
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Young people
Number of subjects: 3030
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sleep duration
Number of subjects: 3030
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive daytime sleepiness
Number of subjects: 3030
Study 10699223 — intervention group
Group type: EXPERIMENTAL
Intervention: Insufficient sleep
Number of subjects: 3030
Study 9337186 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine
Number of subjects: 18
Study 9337186 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 8380243 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir (6 mg/kg once per day after transplant)
Number of subjects: 85
Study 2879752 — intervention group
Group type: EXPERIMENTAL
Intervention: lormetazepam (10 drops twice daily for 4 weeks)
Number of subjects: 10
Study 2879752 — intervention group
Group type: COMPARATOR
Intervention: diazepam (10 drops twice daily for 4 weeks)
Number of subjects: 10
Study 29569476 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral lateral rectus resection under topical anesthesia
Number of subjects: 16
Study 27206733 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention promoting healthy lifestyles, risk screening, and remote support (follow-up).
Number of subjects: 4170
Study 27206733 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided).
Number of subjects: 4170
Study 27206733 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (no specific intervention details provided).
Number of subjects: 4170
Study 27206733 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive dissemination strategy of providing training and materials.
Number of subjects: 4170
Study 25409719 — intervention group
Group type: EXPERIMENTAL
Intervention: Back School program (group A)
Number of subjects: 56
Study 25409719 — intervention group
Group type: COMPARATOR
Intervention: Hydrotherapy program (group B)
Number of subjects: 56
Study 22879423 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of lutein and 2 mg of zeaxanthin per day (intervention group)
Number of subjects: 0
Study 22879423 — intervention group
Group type: COMPARATOR
Intervention: Diet alone (control group)
Number of subjects: 0
Study 20451854 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial rectus slanting recession (SLANT group)
Number of subjects: 18
Study 20451854 — intervention group
Group type: COMPARATOR
Intervention: Medial rectus recession with downward transposition (TRANS group)
Number of subjects: 18
Study 18164454 — intervention group
Group type: EXPERIMENTAL
Intervention: Facet injections
Number of subjects: 0
Study 18164454 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency neurotomy
Number of subjects: 0
Study 16403997 — intervention group
Group type: EXPERIMENTAL
Intervention: Unweighted group (Biodex Unweighing System at 25% body weight reduction)
Number of subjects: 23
Study 16403997 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted group (weighted scuba-diving belt, increasing normal body weight by 5%)
Number of subjects: 23
Study 16403997 — intervention group
Group type: COMPARATOR
Intervention: Treadmill control group (treadmill training with no loading or unloading)
Number of subjects: 23
Study 12745507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch with culturally sensitive self-help quitting materials
Number of subjects: 498
Study 12745507 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch with standard self-help quitting materials
Number of subjects: 498
Study 12745507 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 498
Study 10365496 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural Management (BM)
Number of subjects: 211
Study 10365496 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Sedation (IVS)
Number of subjects: 211
Study 10365496 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide Sedation (NOS)
Number of subjects: 211
Study 10365496 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 211
Study 8894914 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation therapy
Number of subjects: 20
Study 8894914 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 1503282 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (4.9 +/- 0.3 micrograms.kg‐1)
Number of subjects: 77
Study 1503282 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyzine alone (group T)
Number of subjects: 77
Study 6391072 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol combined with 2% pilocarpine
Number of subjects: 103
Study 6391072 — intervention group
Group type: COMPARATOR
Intervention: 0.5% topical timolol combined with 2% pilocarpine
Number of subjects: 103
Study 29233588 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and low glycemic index diet (LGI)
Number of subjects: 103
Study 29233588 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate and high glycemic index diet (HGI)
Number of subjects: 103
Study 29233588 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat and high glycemic index diet (LF)
Number of subjects: 103
Study 29233588 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diets (general)
Number of subjects: 103
Study 30344165 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and fluorouracil (TF) concurrent with radiotherapy
Number of subjects: 321
Study 30344165 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and cisplatin (TP) concurrent with radiotherapy
Number of subjects: 321
Study 30344165 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and carboplatin (TC) concurrent with radiotherapy
Number of subjects: 321
Study 27770771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (5 mg once daily for 12 weeks, with dose titration to 10 mg allowed)
Number of subjects: 133
Study 24246508 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training (1 hour once a week for 10 weeks, aerobic exercises at 60-80% work capacity, resistance training, dyspnoea management)
Number of subjects: 78
Study 24246508 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 78
Study 24246508 — intervention group
Group type: COMPARATOR
Intervention: Control group (individual instruction in exercise training)
Number of subjects: 78
Study 23158730 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day sequential therapy (omeprazole 0.8 - 1.0 mg/(kg·d) + amoxicillin-clavulanate 50 mg/(kg·d) for 5 days, followed by omeprazole 0.8 - 1.0 mg/(kg·d), clarithromycin 20 mg/(kg·d), and metronidazole 20 mg/(kg·d) for 5 days)
Number of subjects: 214
Study 23158730 — intervention group
Group type: COMPARATOR
Intervention: 7-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 7 days)
Number of subjects: 214
Study 23158730 — intervention group
Group type: COMPARATOR
Intervention: 10-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 10 days)
Number of subjects: 214
Study 23158730 — intervention group
Group type: COMPARATOR
Intervention: 14-day triple therapy (omeprazole 0.8 - 1.0 mg/(kg·d), amoxicillin-clavulanate 50 mg/(kg·d), and clarithromycin 20 mg/(kg·d) for 14 days)
Number of subjects: 214
Study 19843084 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing emollient
Number of subjects: 60
Study 19843084 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 60
Study 18496884 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT) - 10 sessions of 2 hours, twice weekly
Number of subjects: 25
Study 18496884 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Stimulation (CS) - 8 sessions of 1.5 hours, once weekly
Number of subjects: 25
Study 15848712 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 donor hearts (medically unsuitable)
Number of subjects: 144
Study 15848712 — intervention group
Group type: COMPARATOR
Intervention: Group 2 donor hearts (medically suitable)
Number of subjects: 144
Study 12484580 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information sheet
Number of subjects: 126
Study 12484580 — intervention group
Group type: COMPARATOR
Intervention: Verbal information
Number of subjects: 126
Study 9787945 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral formulation (1:1 dose-ratio conversion)
Number of subjects: 30
Study 9787945 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral formulation (0.75 dose-ratio conversion)
Number of subjects: 30
Study 9787945 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral formulation (1:1 and 0.75 dose-ratio conversion)
Number of subjects: 30
Study 9787945 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (three blood samples post-dosing of Neoral formulation)
Number of subjects: 30
Study 9787945 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoral formulation
Number of subjects: 30
Study 7707126 — intervention group
Group type: COMPARATOR
Intervention: Interferon alfa‐2a (3 x 10(6) U subcutaneously three times per week)
Number of subjects: 313
Study 7707126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin (4 mg/m2 intravenously every 2 weeks)
Number of subjects: 313
Study 7707126 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 313
Study 2697951 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (DMSO)
Number of subjects: 42
Study 46951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic-acid analogue (N.A.A.) given within 12 hours of myocardial infarction onset
Number of subjects: 81
Study 46951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic-acid analogue (N.A.A.)
Number of subjects: 81
Study 46951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 31924718 — intervention group
Group type: EXPERIMENTAL
Intervention: Projection Space Synthesis (PSS)
Number of subjects: 140
Study 31924718 — intervention group
Group type: COMPARATOR
Intervention: Image Space Synthesis (PIS)
Number of subjects: 140
Study 30519704 — intervention group
Group type: EXPERIMENTAL
Intervention: Slip-resistant footwear (SRF) program
Number of subjects: 226
Study 30519704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SRF program)
Number of subjects: 226
Study 27650383 — intervention group
Group type: EXPERIMENTAL
Intervention: Two primary endpoints in the Social Fitness study
Number of subjects: 0
Study 27650383 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of superiority and non-inferiority aims for the endpoints
Number of subjects: 0
Study 25874122 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhibitory control (Go‐Nogo paradigm)
Number of subjects: 498
Study 25874122 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive flexibility task
Number of subjects: 498
Study 25874122 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained attention task
Number of subjects: 498
Study 23328339 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational treatment (9 sessions of 2 hours each: 5 sessions of education about the illness + 4 sessions of autogenic relaxation)
Number of subjects: 216
Study 23328339 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational treatment
Number of subjects: 216
Study 20683595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg every 3 weeks for six cycles
Number of subjects: 70
Study 20683595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg every 3 weeks for six cycles
Number of subjects: 70
Study 20683595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (both dosages)
Number of subjects: 70
Study 19244366 — intervention group
Group type: EXPERIMENTAL
Intervention: Oily fish (average of one serving every 5 days)
Number of subjects: 1119
Study 19244366 — intervention group
Group type: EXPERIMENTAL
Intervention: Wine (average of half a glass a day)
Number of subjects: 1119
Study 19244366 — intervention group
Group type: COMPARATOR
Intervention: Dietary patterns
Number of subjects: 1119
Study 16322108 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed gastric emptying (defined as at least 6.3% residual volume at four hours)
Number of subjects: 864
Study 16322108 — intervention group
Group type: EXPERIMENTAL
Intervention: SF 36 physical composite score (PCS)
Number of subjects: 864
Study 16322108 — intervention group
Group type: EXPERIMENTAL
Intervention: SF 36 mental composite score (MCS)
Number of subjects: 864
Study 16322108 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher symptom scores for fullness, epigastric pain, and nausea
Number of subjects: 864
Study 16322108 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline nausea symptom score, lower gastric emptying rates at one hour, and lower body mass index
Number of subjects: 864
Study 16322108 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex, epigastric pain, and nausea
Number of subjects: 864
Study 10227503 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual 1-hyoscyamine sulfate
Number of subjects: 110
Study 10227503 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 10227503 — intervention group
Group type: COMPARATOR
Intervention: No medication
Number of subjects: 110
Study 9772597 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine combined with cord blood infusion
Number of subjects: 48
Study 9772597 — intervention group
Group type: COMPARATOR
Intervention: Cord blood infusion solely
Number of subjects: 48
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 capsules of fish oil daily for 6 months
Number of subjects: 28
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 capsules of fish oil daily for 6 months
Number of subjects: 28
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 capsules of fish oil daily for 6 months
Number of subjects: 28
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 capsules of fish oil daily for 6 months
Number of subjects: 28
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses except the lowest
Number of subjects: 28
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest dose (12 capsules)
Number of subjects: 28
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: Two middle doses (6 and 9 capsules)
Number of subjects: 28
Study 1832701 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids consumption
Number of subjects: 28
Study 6227208 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure during isometric exercise (in upper blood pressure range)
Number of subjects: 120
Study 6227208 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hour urinary noradrenaline excretion (in upper blood pressure range)
Number of subjects: 120
Study 6227208 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma aldosterone (in upper blood pressure range)
Number of subjects: 120
Study 6227208 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose (in intermediate blood pressure range)
Number of subjects: 120
Study 6227208 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma insulin (in intermediate blood pressure range)
Number of subjects: 120
Study 31527690 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for triglycerides (TG)
Number of subjects: 4080
Study 31527690 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for high density lipoprotein cholesterol (HDL)
Number of subjects: 4080
Study 31527690 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for low density lipoprotein cholesterol (LDL)
Number of subjects: 4080
Study 31527690 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic lipid scores for total cholesterol (TC)
Number of subjects: 4080
Study 31527690 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use (overall)
Number of subjects: 4080
Study 31527690 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipophilic statins
Number of subjects: 4080
Study 29962429 — intervention group
Group type: EXPERIMENTAL
Intervention: PYC chewing gum (2.5 mg per piece, 2 pieces, 6 times daily for 15 min)
Number of subjects: 21
Study 29962429 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum (sugar-free gums)
Number of subjects: 21
Study 26960972 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced narrative game group
Number of subjects: 0
Study 26960972 — intervention group
Group type: COMPARATOR
Intervention: Self-monitoring group
Number of subjects: 0
Study 25179924 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis-first condition (non-analytic reasoning)
Number of subjects: 73
Study 25179924 — intervention group
Group type: COMPARATOR
Intervention: Features-first condition (analytic reasoning)
Number of subjects: 73
Study 21853290 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg tolvaptan with 240 mL of reconstituted grapefruit juice
Number of subjects: 20
Study 21853290 — intervention group
Group type: COMPARATOR
Intervention: 60 mg tolvaptan with 240 mL of water
Number of subjects: 20
Study 20805116 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral internal mammary arteries (BIMA)
Number of subjects: 3102
Study 20805116 — intervention group
Group type: COMPARATOR
Intervention: Single internal mammary artery (SIMA)
Number of subjects: 3102
Study 18052518 — intervention group
Group type: EXPERIMENTAL
Intervention: Kids Living Fit (KLF) program
Number of subjects: 185
Study 18052518 — intervention group
Group type: COMPARATOR
Intervention: No-intervention/contrast group
Number of subjects: 185
Study 15617666 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult feature search
Number of subjects: 0
Study 15617666 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult conjunction search
Number of subjects: 0
Study 15617666 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial-configuration search
Number of subjects: 0
Study 11877767 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8 at doses of 261-495 mCi, with a protein dose of 2.5 mg/kg (or 10 mg/kg for one patient with splenomegaly).
Number of subjects: 7
Study 11877767 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose myeloablative radioimmunotherapy with (131)I-labeled chimeric anti-CD20 antibody C2B8.
Number of subjects: 7
Study 10223779 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg/h lanreotide
Number of subjects: 20
Study 10223779 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg/h lanreotide
Number of subjects: 20
Study 10223779 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 microg/h lanreotide
Number of subjects: 20
Study 10223779 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of lanreotide
Number of subjects: 20
Study 10223779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7797662 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography in controls
Number of subjects: 22
Study 7797662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography in Tietze's syndrome
Number of subjects: 22
Study 7797662 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography correlation with CT
Number of subjects: 22
Study 2367653 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood patch technique (group A)
Number of subjects: 100
Study 2367653 — intervention group
Group type: COMPARATOR
Intervention: No blood patch (group B)
Number of subjects: 100
Study 30797042 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Bridge Treatment (BBT)
Number of subjects: 320
Study 30797042 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 320
Study 29848186 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient and physician interventions (Cohort C)
Number of subjects: 600
Study 29848186 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician intervention (Cohort B)
Number of subjects: 600
Study 29848186 — intervention group
Group type: COMPARATOR
Intervention: No interventions (Cohort A)
Number of subjects: 600
Study 26801394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cancer Home-Life Intervention in addition to usual care
Number of subjects: 272
Study 26801394 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 272
Study 25106091 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Dudes intervention (rewards, peer-modeling, food exposure)
Number of subjects: 560
Study 25106091 — intervention group
Group type: COMPARATOR
Intervention: Control group (only provided with fruits and vegetables)
Number of subjects: 560
Study 21926656 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (2 mg/kg)
Number of subjects: 24
Study 21926656 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24
Study 20589922 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg paliperidone ER OROS
Number of subjects: 24
Study 20589922 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 mg paliperidone ER OROS
Number of subjects: 24
Study 17379842 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (20 mg/d)
Number of subjects: 12